Aastrom Biosciences aims to price public offering of its common stock

Proceeds will fund phase 2b ixCELL-DCM clinical trial of ixmyelocel-T

By Devika Patel

Knoxville, Tenn., Aug. 6 – Aastrom Biosciences Inc. will price a public offering of common stock with a greenshoe, according to a Form S-1 filed Thursday with the Securities and Exchange Commission.

Proceeds will be used to support commercialization of products, for development of the company’s phase 2b ixCELL-DCM clinical trial of ixmyelocel-T and other preclinical studies, as well as for working capital and general corporate purposes.

Aastrom is a biotechnology company based in Ann Arbor, Mich.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.